Human milk oligosaccharides for modulating inflammation

Abstract

Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.

What is claimed is: 
     
         1 . A synthetic pediatric formula for modulating respiratory virus-induced inflammation, the synthetic pediatric formula comprising a mixture of 3′-sialyllactose and 6′-sialyllactose in a concentration of from about 0.001 mg/mL to about 20 mg/mL, wherein the 3′-sialyllactose is present in an amount of from about 0.001 mg/mL to less than 0.15 mg/mL. 
     
     
         2 . The synthetic pediatric formula of  claim 1 , comprising from 0.001 mg/mL to less than 0.23 mg/mL of the mixture of 3′-sialyllactose and 6′-sialyllactose. 
     
     
         3 . The synthetic pediatric formula of  claim 1 , comprising from 0.001 mg/mL to less than 0.15 mg/mL of the mixture of 3′-sialyllactose and 6′-sialyllactose. 
     
     
         4 . The synthetic pediatric formula of  claim 1 , comprising greater than 0.65 mg/mL to 20 mg/mL of the mixture of 3′-sialyllactose and 6′-sialyllactose. 
     
     
         5 . The synthetic pediatric formula of  claim 1 , wherein 6′-sialyllactose is present in a concentration of from 0.001 mg/mL to less than 0.25 mg/mL. 
     
     
         6 . The synthetic pediatric formula of  claim 1 , wherein 6′-sialyllactose is present in a concentration of from greater than 0.4 mg/mL to 20 mg/mL. 
     
     
         7 . A method of inhibiting the growth of respiratory viruses in an infant, toddler, or child, the method comprising:
 identifying an infant, toddler, or child having a respiratory virus; and   administering to the infant, toddler, or child a composition comprising lacto-N-neotetraose in an concentration of from about 0.001 mg/mL to about 0.2 mg/mL.   
     
     
         8 . The method of  claim 7 , wherein the lacto-N-neotetraose is present in a concentration of from about 0.001 mg/mL to about 0.1 mg/mL. 
     
     
         9 . The method of  claim 7 , wherein the composition further comprises from 0.001 mg/mL to less than 0.25 mg/mL 6′-sialylallactose. 
     
     
         10 . The method of  claim 7 , wherein the composition further comprises from 0.001 mg/mL to less than 0.15 mg/mL 3′-sialylallactose. 
     
     
         11 . The method of  claim 7 , wherein the composition further comprises 3′-sialyllactose and 6′-sialyllactose in a weight ratio of 3′-sialyllactose to 6′-sialyllactose of from about 1:20 to about 20:1. 
     
     
         12 . The method of  claim 7 , wherein the composition further comprises 3′-sialyllactose and 6′-sialyllactose in a weight ratio of 3′-sialyllactose to 6′-sialyllactose of from about 1:2 to about 2:1.